IRONWOOD PHARMACEUTICALS, INC. Remaining Share Repurchase Authorization
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Remaining Share Repurchase Authorization of $32.40 million as of 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 · last filed 2022-05-05
- 2022-03-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $32.40M.
- 2021-12-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $122.90M.
| Period end | Stock Repurchase Program, Remaining Authorized Repurchase Amount |
|---|---|
| 2022-03-31 | $32.40M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $122.90M 10-K · filed 2022-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |